Monday, April 6, 2020
Home WuXi News Volume #001 - June 2019

Volume #001 - June 2019

WuXi AppTec’s Enabling Capability Recognized by Partners and Philadelphia Authority at BIO 2019

By WuXi Content Team WuXi AppTec’s enabling capabilities and contribution to the development of life science were recognized by both its many partners and the City of Philadelphia at the BIO International...

insitro’s Daphne Koller Discusses Machine Learning, Predictive Biology and Therapeutic Approaches for Nonalcoholic Steatohepatitis...

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) insitro’s CEO Daphne Koller is no stranger to the world of experimental biology. As the Rajeev Motwani of Professor of Computer Science...

STORM Therapeutics Pioneering New RNA Pathways to Novel Therapies

In August of 2018 the Food and Drug Administration (FDA) approved the first of a potentially game-changing class of drugs called small interfering ribonucleic acid (siRNA). FDA Commissioner Scott Gottlieb, MD...

The Fight Against Acute Microbial Resistance (AMR) goes Virtual – Acurx Developing Antimicrobials with...

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) Bob DeLuccia is a man on the move with a single mission:  Addressing the worldwide epidemic of antimicrobial drug resistance, today commonly...

The Game-Changing Potential of Targeting RNA with Small Molecules: More Than Turning the Undruggable...

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) Once considered impossible, targeting RNA with small molecules has the potential to be a game-changer. It’s convincing enough to industry veteran Michael...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Reports Strong 2019 Annual Results

WuXi AppTec Reports Strong 2019 Annual Results Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted...